source
- Definium Therapeutics reports positive Phase 3 results for oral LSD anxiety drug DT120Definium Therapeutics announced Monday that its experimental oral LSD formulation, DT120, achieved positive outcomes in a Phase 3 trial targeting an anxiety disorder. The trial, the company's thir…
- Public backing fuels FDA hearing on psychedelic therapies and potential COMP360 approvalThe FDA is holding a hearing on Monday to discuss the future of psychedelic drug development, after a wave of public comments expressed strong support for further research. Analysts say the suppor…